(RTTNews) - Fresenius SE & Co. KGaA (FRE.DE) said Thursday its supervisory board appointed Marc-Alexander Mahl to the management board, effective November 1, 2026, with responsibility for the Fresenius Kabi businesses.
(RTTNews) - Asian stocks advanced on Friday as tech shares bounced back following Federal Reserve Chair Kevin Warsh's comments at the IMF-World Bank meetings in Bangkok that artificial intelligence is a major force in the global economy.
Fintel reports that on October 15, 2026, JP Morgan upgraded their outlook for Brighthouse Financial, Inc. - Preferred Stock (NASDAQGS:BHFAM) from Underweight to Neutral. Brighthouse Financial, Inc., based in the United States, operates primarily in the insurance industry, focusin
(RTTNews) - Man Group plc (EMG.L, MNGPY.PK, MNGPF.PK), an investment management firm, on Friday issued a trading statement, reporting sequentially higher assets under management for the third quarter ended September 30.
(RTTNews) - On Friday, Roche Holding AG (RHHBY) announced that the U.S. Food and Drug Administration approved Enspryng for adults with thyroid eye disease, making it the first at-home subcutaneous treatment option for the condition.
Key PointsNebius currently demonstrates higher overall revenue generation than Innodata, leading the comparison in five of the eight available quarters.
(RTTNews) - German wind turbine manufacturer Nordex Group (NDX1.DE, NRDXF.PK) on Friday announced preliminary third-quarter results, expecting year-over-year growth in revenues and EBITDA, above market estimates, supported by improved service profitability. Further, the firm rais
Key PointsServiceNow currently generates higher overall revenue than CrowdStrike, establishing a clear lead in each of the past eight quarters while both operations steadily scale their top-line results in a predictable upward trajectory.
(RTTNews) - Sanofi (SNY) said Thursday it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) and signed a letter of intent, or LOI for Dupixent across four additional indications in dermatology and respiratory.
(RTTNews) - Nanjing Leads Biolabs Co., Ltd. (9887.HK) said Friday it dosed the first patient in an open-label, multicenter Phase 1b/2 trial evaluating Opamtistomig, or LBL-024, in combination therapy for metastatic colorectal cancer.